LEVOMETHADYL ACETATE HYDROCHLORIDE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C23H31NO2.ClH
Molecular Weight	389.959
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of LEVOMETHADYL ACETATE HYDROCHLORIDE

Structure Search

SMILES

Cl.CC[C@H](OC(C)=O)C(C[C@H](C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2

InChI

InChIKey=UXBPQRGCVJOTNT-COBSGTNCSA-N

InChI=1S/C23H31NO2.ClH/c1-6-22(26-19(3)25)23(17-18(2)24(4)5,20-13-9-7-10-14-20)21-15-11-8-12-16-21;/h7-16,18,22H,6,17H2,1-5H3;1H/t18-,22-;/m0./s1

HIDE SMILES / InChI

Molecular Formula	C23H31NO2
Molecular Weight	353.4977
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Approval Year

C_max

Value	Dose	Analyte	Population
139 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15380290	80 mg 1 times / 2 days steady-state, oral dose: 80 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	DINORACETYLMETHADOL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
184 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15380290	80 mg 1 times / 2 days steady-state, oral dose: 80 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	NORACYMETHADOL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
188 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15380290	80 mg 1 times / 2 days steady-state, oral dose: 80 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	LEVOMETHADYL ACETATE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
5892 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15380290	80 mg 1 times / 2 days steady-state, oral dose: 80 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	DINORACETYLMETHADOL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
6056 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15380290	80 mg 1 times / 2 days steady-state, oral dose: 80 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	NORACYMETHADOL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2995 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15380290	80 mg 1 times / 2 days steady-state, oral dose: 80 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	LEVOMETHADYL ACETATE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
3 mg/kg multiple, oral Studied dose Dose: 3 mg/kg Route: oral Route: multiple Dose: 3 mg/kg Sources: https://pubmed.ncbi.nlm.nih.gov/11760927/	unhealthy, 23 - 57 years n = 6 Health Status: unhealthy Condition: heroin dependency Age Group: 23 - 57 years Sex: M+F Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/11760927/	Disc. AE: Cardiotoxicity... AEs leading to discontinuation/dose reduction: Cardiotoxicity (6 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/11760927/

AEs

AE	Significance	Dose	Population
Cardiotoxicity	6 patients Disc. AE	3 mg/kg multiple, oral Studied dose Dose: 3 mg/kg Route: oral Route: multiple Dose: 3 mg/kg Sources: https://pubmed.ncbi.nlm.nih.gov/11760927/	unhealthy, 23 - 57 years n = 6 Health Status: unhealthy Condition: heroin dependency Age Group: 23 - 57 years Sex: M+F Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/11760927/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1737	substrate 1037	substrate 1217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	CYP1A2 1054 CYP2A6 543 CYP2B6 664 CYP2C8 693 CYP2C18 138 CYP2E1 667

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP1A2 1054	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/15104241/ Page: 7.0	minor
CYP2A6 543	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/15104241/ Page: 7.0	minor
CYP2B6 664	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/15104241/ Page: 7.0	minor
CYP2C18 138	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/15104241/ Page: 7.0	minor
CYP2C8 693	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/15104241/ Page: 7.0	minor
CYP2C9 1037	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/15104241/ Page: 7.0	minor
CYP2D6 1217	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/15104241/ Page: 7.0	minor
CYP2E1 667	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/15104241/ Page: 7.0	minor
CYP3A4 1737	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/11259570/;https://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Roxane/Orlaam/Orlaam%20Oral%20Solution%2010mg%20per%20mL.pdf	yes	likely (co-administration study) Comment: the addition of drugs that induce this enzyme (such as rifampin, phenobarbital, and phenytoin) or inhibit this enzyme (such as ketoconazole, erythromycin, and saquinavir) could increase the levels of parent drug or its active metabolites in a patient that was previously at steady-state, and this could potentially precipitate serious arrhythmias, including torsade de pointes Sources: https://pubmed.ncbi.nlm.nih.gov/11259570/;https://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Roxane/Orlaam/Orlaam%20Oral%20Solution%2010mg%20per%20mL.pdf

Sourcing

Vendor/Aggregator	ID	URL
ABI Chem	AC1L21LS
Ambinter	Amb22336843	http://www.ambinter.com/reference/22336843
Aurora Fine Chemicals LLC	A17.900.919	http://online.aurorafinechemicals.com/info?ID=A17.900.919
Chemieliva Pharmaceutical Co., Ltd	PBCM1306631
Glentham Life Sciences	GL4015	http://www.glentham.com/products/product/GL4015/
NovoSeek	39371
PubChem	39371	https://pubchem.ncbi.nlm.nih.gov/compound/39371
Sigma-Aldrich	L7418_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/l7418?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Smolecule	S532971	http://www.smolecule.com/products/s532971
THE BioTek	bt-273431	https://www.thebiotek.com/product/inhibitors/bt-273431

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:14:21 GMT 2023` Edited by `admin` on `Fri Dec 15 15:14:21 GMT 2023`
Record UNII	B54CW5KG52
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

LEVOMETHADYL ACETATE HYDROCHLORIDE

Official Name

English

LEVACETYLMETHADOL HYDROCHLORIDE [MART.]

Common Name

English

MK790

Code

English

LEVOMETHADYL ACETATE HYDROCHLORIDE [MI]

Common Name

English

ORLAAM

Brand Name

English

LEVOMETHADYL ACETATE HCL

Common Name

English

LEVOMETHADYL ACETATE HYDROCHLORIDE [ORANGE BOOK]

Common Name

English

MK-790

Code

English

LEVOMETHADYL ACETATE HYDROCHLORIDE [USAN]

Common Name

English

BENZENEETHANOL, .BETA.-(2-(DIMETHYLAMINO)PROPYL)-.ALPHA.-ETHYL-.BETA.-PHENYL-, ACETATE (ESTER), HYDROCHLORIDE, (S-(R*,R*))-

Common Name

English

LEVOMETHADYL ACETATE HYDROCHLORIDE [VANDF]

Common Name

English

(-)-(3S,6S)-6-(DIMETHYLAMINO)-4,4-DIPHENYL-3-HEPTANOL ACETATE (ESTER), HYDROCHLORIDE

Common Name

English

Levomethadyl acetate hydrochloride [WHO-DD]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C67413